Cargando…

CD44 as a tumor biomarker and therapeutic target

CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberrant expression and dysregulation of CD44 contribute to tumor initiation and progression. CD4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Hanxiao, Niu, Mengke, Yuan, Xun, Wu, Kongming, Liu, Aiguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727191/ https://www.ncbi.nlm.nih.gov/pubmed/33303029 http://dx.doi.org/10.1186/s40164-020-00192-0

Ejemplares similares

The role of CD44 in epithelial–mesenchymal transition and cancer development
por: Xu, Hanxiao, et al.
Publicado: (2015)

DACH1 suppresses breast cancer as a negative regulator of CD44
por: Xu, Hanxiao, et al.
Publicado: (2017)

CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer
por: Xu, Hanxiao, et al.
Publicado: (2016)

Tumor organoids: applications in cancer modeling and potentials in precision medicine
por: Xu, Hanxiao, et al.
Publicado: (2022)

Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis
por: Xu, Hanxiao, et al.
Publicado: (2016)

The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer
por: Thapa, Ranjeeta, et al.
Publicado: (2016)

Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
por: Yuan, Xun, et al.
Publicado: (2014)

Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Regulation of PD-L1 expression in the tumor microenvironment
por: Yi, Ming, et al.
Publicado: (2021)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Understanding Hyaluronan Receptor (CD44) Interaction, HA-CD44 Activated Potential Targets in Cancer Therapeutics
por: Chaudhry, Gul-e-Saba, et al.
Publicado: (2021)

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
por: Wu, Yuze, et al.
Publicado: (2022)

CD44 Glycosylation as a Therapeutic Target in Oncology
por: Liao, Chengcheng, et al.
Publicado: (2022)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
por: Sun, Wei, et al.
Publicado: (2015)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
por: Xu, Hanxiao, et al.
Publicado: (2017)

CD44: A metastasis driver and therapeutic target
por: Sottnik, Joseph L., et al.
Publicado: (2016)

Lipid-Based Nanovectors for Targeting of CD44-Overexpressing Tumor Cells
por: Arpicco, Silvia, et al.
Publicado: (2013)

DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling
por: Han, Na, et al.
Publicado: (2015)

Advances of Targeted Therapy for Hepatocellular Carcinoma
por: Niu, Mengke, et al.
Publicado: (2021)

The biology and role of CD44 in cancer progression: therapeutic implications
por: Chen, Chen, et al.
Publicado: (2018)

Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cells
por: Niu, Mengke, et al.
Publicado: (2020)

DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/β-catenin signaling
por: Liu, Yu, et al.
Publicado: (2015)

CD44 as a potential diagnostic tumor marker
por: Basakran, Nawwaf S.
Publicado: (2015)

Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
por: Zhu, Shuangli, et al.
Publicado: (2021)

Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma
por: Molejon, Maria Inés, et al.
Publicado: (2015)

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors
por: Geskovski, Nikola, et al.
Publicado: (2021)

The liberation of CD44
por: Cichy, Joanna, et al.
Publicado: (2003)

EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival
por: Xu, Hanxiao, et al.
Publicado: (2019)

Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis
por: Yuan, Xun, et al.
Publicado: (2015)

CD44 in rheumatoid arthritis
por: Naor, David, et al.
Publicado: (2003)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

Chimeric antigen receptor T cells: a novel therapy for solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence
por: Molejon, Maria Inés, et al.
Publicado: (2015)

TIMM44 is a potential therapeutic target of human glioma
por: Guo, Yi-zhuo, et al.
Publicado: (2022)

CD133(+)CD54(+)CD44(+) circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer
por: Fang, Chao, et al.
Publicado: (2016)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022)

Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
por: Bei, Yuncheng, et al.
Publicado: (2023)

Organoid technology and applications in cancer research
por: Xu, Hanxiao, et al.
Publicado: (2018)

Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
por: Xu, Hanxiao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9i1cpkonhvl3ran2jgkamh5tgc